NIPRO CORPORATION Logo

NIPRO CORPORATION

Global manufacturer of renal care devices, injectable drugs, and pharmaceutical packaging.

8086 | T

Overview

Corporate Details

ISIN(s):
JP3673600007
LEI:
Country:
Japan
Address:
摂津市千里丘新町3番26号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Nipro Corporation is a global, comprehensive healthcare manufacturer founded in 1954. The company operates across four primary business segments: Medical Devices, Pharmaceuticals, Pharma Packaging, and Regenerative Medicine. Nipro is a market leader in renal care, providing a wide range of products for hemodialysis, including dialyzers and blood tubing. Its medical device portfolio also encompasses catheters, infusion kits, and blood collection tubes. The pharmaceuticals division specializes in the contract manufacturing of injectable drugs, while the pharma packaging business produces glass products such as vials and ampoules. Nipro focuses on developing unique technologies and products through its research and development sites to serve the needs of frontline medical treatment worldwide.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-21 02:30
Registration Form
発行登録書(株券、社債券等)
Japanese 29.3 KB
2025-11-14 02:30
Registration Form
確認書
Japanese 8.8 KB
2025-11-14 02:30
Interim / Quarterly Report
半期報告書-第73期(2025/04/01-2026/03/31)
Japanese 305.7 KB
2025-07-18 03:47
Prospectus
発行登録追補書類(株券、社債券等)
Japanese 125.7 KB
2025-07-03 03:01
Registration Form
訂正発行登録書
Japanese 9.7 KB
2025-07-03 03:00
AGM Information
臨時報告書
Japanese 36.5 KB
2025-06-27 02:50
Regulatory Filings
訂正発行登録書
Japanese 80.2 KB
2025-06-25 07:25
Governance Information
内部統制報告書-第72期(2024/04/01-2025/03/31)
Japanese 24.8 KB
2025-06-25 07:24
Registration Form
確認書
Japanese 8.7 KB
2025-06-25 07:24
Annual Report
有価証券報告書-第72期(2024/04/01-2025/03/31)
Japanese 1.8 MB
2025-03-25 07:31
Registration Form
訂正発行登録書
Japanese 9.7 KB
2025-03-25 07:30
Board/Management Information
臨時報告書
Japanese 23.8 KB
2025-03-21 07:31
Registration Form
訂正発行登録書
Japanese 9.7 KB
2025-03-21 07:30
Regulatory Filings
臨時報告書
Japanese 19.2 KB
2025-03-03 02:28
Regulatory Filings
訂正発行登録書
Japanese 9.8 KB

Automate Your Workflow. Get a real-time feed of all NIPRO CORPORATION filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NIPRO CORPORATION

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NIPRO CORPORATION via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

JW LIFESCIENCE CORPORATION Logo
A leading developer and manufacturer of infusion solutions, from basic IV fluids to complex nutrients.
South Korea
234080
JW PHARMACEUTICAL Logo
South Korea
001060
JW SHINYAK CORPORATION Logo
Develops specialty medicines for the dermatology, urology, and otolaryngology clinical markets.
South Korea
067290
Jyong Biotech Ltd. Logo
Develops plant-derived drugs for urinary system diseases, with a lead candidate in Phase III trials.
United States of America
MENS
kainos loboratories,inc Logo
Develops, manufactures, and sells innovative clinical diagnostic reagents for the healthcare industry.
Japan
4556
KAKEN PHARMACEUTIAL CO., LTD. Logo
R&D pharma firm creating drugs & devices for orthopedics, dermatology, and surgery globally.
Japan
4521
KALA BIO, Inc. Logo
Developing stem cell-based biologics for rare and serious eye diseases.
United States of America
KALA
Kalaris Therapeutics, Inc. Logo
Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.
United States of America
KLRS
KalVista Pharmaceuticals, Inc. Logo
Developing oral protease inhibitors for rare diseases like hereditary angioedema (HAE).
United States of America
KALV
Kamada Ltd. Logo
Develops specialty plasma-derived therapeutics for rare and serious conditions.
Israel
KMDA

Talk to a Data Expert

Have a question? We'll get back to you promptly.